Literature DB >> 20298675

Direct assessment of P-glycoprotein efflux to determine tumor response to chemotherapy.

Gauri Patwardhan1, Vineet Gupta, Juowen Huang, Xin Gu, Yong-Yu Liu.   

Abstract

Multidrug resistance is a major impediment to the success of cancer chemotherapy. The overproduced P-glycoprotein that extrudes anticancer drugs from cells, is the most common mechanism detected in multidrug-resistant cancers. Direct measurement of cellular efflux of tumors in vivo, rather than estimation of MDR1 mRNA and P-glycoprotein levels in samples stored or embedded, can functionally characterize the mechanism of drug resistance and determine the choice of anticancer drugs for cancer patients. Herewith, we introduce a new approach to directly determine P-glycoprotein efflux of tumors. Employing Flutax-2 (Oregon green-488 paclitaxel) and fluorescence spectrophotometry, this method has successfully measured cellular transportability including efflux and accumulation in diverse cancer cell lines, tumors and other tissues with high reproducibility. With this method, we have quantitatively determined cellular efflux that is correlated with P-glycoprotein levels and the reversal effects of agents in cell lines of breast, ovarian, cervical and colon cancers, and in tumor-bearing mice. It has sensitively detected these alterations of P-glycoprotein efflux in approximately 5mg tumor or other tissues with high confidence. This direct and quick functional assessment has a potential to determine drug resistance in different types of cancers after surgical resection. Further validation of this method in clinic settings for the diagnosis of drug resistance purpose is needed. (c) 2010 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20298675      PMCID: PMC2860649          DOI: 10.1016/j.bcp.2010.03.010

Source DB:  PubMed          Journal:  Biochem Pharmacol        ISSN: 0006-2952            Impact factor:   5.858


  50 in total

1.  Isolation of amplified and overexpressed DNA sequences from adriamycin-resistant human breast cancer cells.

Authors:  C R Fairchild; S P Ivy; C S Kao-Shan; J Whang-Peng; N Rosen; M A Israel; P W Melera; K H Cowan; M E Goldsmith
Journal:  Cancer Res       Date:  1987-10-01       Impact factor: 12.701

2.  Study of membrane orientation and glycosylated extracellular loops of mouse P-glycoprotein by in vitro translation.

Authors:  J T Zhang; V Ling
Journal:  J Biol Chem       Date:  1991-09-25       Impact factor: 5.157

3.  P-glycoprotein expression and schedule dependence of adriamycin cytotoxicity in human colon carcinoma cell lines.

Authors:  G M Lai; Y N Chen; L A Mickley; A T Fojo; S E Bates
Journal:  Int J Cancer       Date:  1991-11-11       Impact factor: 7.396

Review 4.  Biochemistry of multidrug resistance mediated by the multidrug transporter.

Authors:  M M Gottesman; I Pastan
Journal:  Annu Rev Biochem       Date:  1993       Impact factor: 23.643

Review 5.  Clinical significance of P-glycoprotein in multidrug resistance malignancies.

Authors:  R J Arceci
Journal:  Blood       Date:  1993-05-01       Impact factor: 22.113

6.  Reversal of multidrug resistance in human colon cancer cells expressing the human MDR1 gene by liposomes in combination with monoclonal antibody or verapamil.

Authors:  S Sela; S R Husain; J W Pearson; D L Longo; A Rahman
Journal:  J Natl Cancer Inst       Date:  1995-01-18       Impact factor: 13.506

Review 7.  Anti-apoptotic mechanisms of drug resistance in cancer.

Authors:  T R Wilson; P G Johnston; D B Longley
Journal:  Curr Cancer Drug Targets       Date:  2009-05       Impact factor: 3.428

8.  Functional imaging of multidrug-resistant P-glycoprotein with an organotechnetium complex.

Authors:  D Piwnica-Worms; M L Chiu; M Budding; J F Kronauge; R A Kramer; J M Croop
Journal:  Cancer Res       Date:  1993-03-01       Impact factor: 12.701

9.  Characterization of multidrug resistance by fluorescent dyes.

Authors:  D Kessel; W T Beck; D Kukuruga; V Schulz
Journal:  Cancer Res       Date:  1991-09-01       Impact factor: 12.701

10.  Inhibition of N-linked glycosylation of P-glycoprotein by tunicamycin results in a reduced multidrug resistance phenotype.

Authors:  R Kramer; T K Weber; R Arceci; N Ramchurren; W V Kastrinakis; G Steele; I C Summerhayes
Journal:  Br J Cancer       Date:  1995-04       Impact factor: 7.640

View more
  15 in total

1.  The opposite effects of doxorubicin on bone marrow stem cells versus breast cancer stem cells depend on glucosylceramide synthase.

Authors:  Kaustubh N Bhinge; Vineet Gupta; Salman B Hosain; Seetharama D Satyanarayanajois; Sharon A Meyer; Benny Blaylock; Qian-Jin Zhang; Yong-Yu Liu
Journal:  Int J Biochem Cell Biol       Date:  2012-06-19       Impact factor: 5.085

Review 2.  Sphingolipids and expression regulation of genes in cancer.

Authors:  Gauri A Patwardhan; Yong-Yu Liu
Journal:  Prog Lipid Res       Date:  2010-10-21       Impact factor: 16.195

3.  Differential Coupling of Binding, ATP Hydrolysis, and Transport of Fluorescent Probes with P-Glycoprotein in Lipid Nanodiscs.

Authors:  Mavis Jiarong Li; Abhinav Nath; William M Atkins
Journal:  Biochemistry       Date:  2017-05-04       Impact factor: 3.162

4.  Glucosylceramide synthase, a factor in modulating drug resistance, is overexpressed in metastatic breast carcinoma.

Authors:  Yong-Yu Liu; Gauri A Patwardhan; Ping Xie; Xin Gu; Armando E Giuliano; Myles C Cabot
Journal:  Int J Oncol       Date:  2011-05-23       Impact factor: 5.650

5.  Synthesis of a Fluorescent Analogue of Paclitaxel That Selectively Binds Microtubules and Sensitively Detects Efflux by P-Glycoprotein.

Authors:  Molly M Lee; Zhe Gao; Blake R Peterson
Journal:  Angew Chem Int Ed Engl       Date:  2017-05-09       Impact factor: 15.336

6.  Inhibition of mdr1 by G-quadruplex oligonucleotides and reversal of paclitaxel resistance in human ovarian cancer cells.

Authors:  Biao Wang; Shuo Li; Xin Meng; Hong Shang; Yifu Guan
Journal:  Tumour Biol       Date:  2015-03-24

7.  Glucosylceramide synthase upregulates MDR1 expression in the regulation of cancer drug resistance through cSrc and beta-catenin signaling.

Authors:  Yong-Yu Liu; Vineet Gupta; Gauri A Patwardhan; Kaustubh Bhinge; Yunfeng Zhao; Jianxiong Bao; Harihara Mehendale; Myles C Cabot; Yu-Teh Li; S Michal Jazwinski
Journal:  Mol Cancer       Date:  2010-06-11       Impact factor: 27.401

8.  Influence of Alternative Tubulin Inhibitors on the Potency of a Epirubicin-Immunochemotherapeutic Synthesized with an Ultra Violet Light-Activated Intermediate: Influence of incorporating an internal/integral disulfide bond structure and Alternative Tubulin/Microtubule Inhibitors on the Cytotoxic Anti-Neoplastic Potency of Epirubicin-(C3-amide)-Anti-HER2/neu Synthesized Utilizing a UV-Photoactivated Anthracycline Intermediate.

Authors:  C P Coyne; Toni Jones; Ryan Bear
Journal:  Cancer Clin Oncol       Date:  2012-11

9.  GCS overexpression is associated with multidrug resistance of human HCT-8 colon cancer cells.

Authors:  Min Song; Weidong Zang; Baohua Zhang; Jing Cao; Guanrui Yang
Journal:  J Exp Clin Cancer Res       Date:  2012-03-16

10.  Anti-Neoplastic Cytotoxicity of Gemcitabine-(C4-amide)-[anti-HER2/neu] in Combination with Griseofulvin against Chemotherapeutic-Resistant Mammary Adenocarcinoma (SKBr-3).

Authors:  C P Coyne; Toni Jones; Ryan Bear
Journal:  Med Chem (Los Angeles)       Date:  2013-05
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.